ClinicalTrials.gg
CompletedNCT05414591Updated Jul 13, 2022

Pharmacokinetics and Safety Following Administration of DWP16001

A Phase 1 interventional study of DWP16001 drug A and DWP16001 drug B in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-13.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled May 2021, registered Jun 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

To compare and evaluate the safety and pharmacokinetic characteristics after administration of DWP16001 Drug A and DWP16001 Drug B in healthy adult volunteers

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult volunteers aged ≥ 19 years at screening
  • Subjects with a body weight of ≥ 50.0 kg to ≤ 90.0 kg with a (BMI) of ≥ 18.0 kg/m2 and ≤ 30.0 kg/m2
  • Subjects with no congenital or chronic disease that requires treatment, and no clinical symptoms or findings based on medical examination
  • Subjects who are determined eligible to participate in this study based on results of laboratory tests, vital signs, physical examination etc at screening.

Exclusion criteria

Exclusion Criteria:

  • Current or history of hepatic, renal, nervous, respiratory, endocrine, hemato-oncology, cardiovascular, urogenital, psychosis disorder
  • Current or history of gastrointestinal disorders or prior history of gastrointestinal surgery that may affect safety and PK/PD assessment of the study drug
  • Clinical laboratory test values are outside the accepted normal range at screening
  • Other exclusive inclusion criteria, as defined in the protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Sequence group A

    DWP16001 A mg 1T

    Drug: DWP16001 drug A · Drug: DWP16001 drug B

  • Experimental
    Sequence group B

    DWP16001 B mg 3T

    Drug: DWP16001 drug A · Drug: DWP16001 drug B

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0_t of DWP16001

    Area under the plasma concentration versus time curve

    Time frame: 0-72 hours

  2. Cmax of DWP16001

    Peak Plasma Concetration

    Time frame: 0-72 hours

Secondary outcomes

  1. Tmax Tmax

    Time at Cmax Tmax

    Time frame: 0-72 hours

  2. AUC of DWP16001

    Area under the plasma concentration versus time curve

    Time frame: 0-72 hours

  3. T 1/2 of DWP16001

    half life of DWP16001

    Time frame: 0-72 hours

  4. CL/F of DWP16001

    Apparent total clearance of the drug from plasma after oral administration

    Time frame: 0-72 hours

  5. Vd/F of DWP16001

    Volume of distribution

    Time frame: 0-72 hours

07

Study locations

1 site
  • CHA Bundang Medical Center, CHA University
    Seongnam-si, Gyeonggi-do 13496, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Aug 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2022
First posted
Jun 10, 2022
StartActual
May 1, 2021
Primary completionActual
Aug 1, 2021
CompletionActual
Aug 1, 2021
Last update
Jul 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05414591
Responsible party
Sponsor
First posted
Jun 10, 2022
Start date
May 1, 2021
Primary completion
Aug 1, 2021
Completion
Aug 1, 2021
Last update
Jul 13, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion